92.1 million American adults have at least one type of cardiovascular disease2
When recommending an analgesic, it’s important to consider patients’ heart risks. The combination of certain pain relievers with some medicinal therapies can interfere with cardiovascular treatment. Because of its safety and analgesic efficacy, the American Heart Association has identified acetaminophen as a first-line pain relief option for patients with, or at high risk for, cardiovascular disease.3*
50 million American adults are on aspirin heart therapy4
Ibuprofen may inhibit aspirin’s cardioprotective benefits. Ibuprofen binds to the cyclooxygenase (COX-1) enzyme, which can interfere with aspirin’s ability to bind to COX-1 and exert its antiplatelet effect.1*
Watch ibuprofen interfere with aspirin’s cardioprotective benefits—and learn how TYLENOL® does not1
Aspirin binds to platelet COX-1 to inhibit platelet aggregation and to protect against myocardial infarction. Ibuprofen binds to the same area of the COX-1 enzyme. When a patient takes ibuprofen prior to taking aspirin, aspirin is blocked from reaching its binding sites.1 Adding an NSAID to aspirin can also increase the risk of stomach bleeding.5
TYLENOL® does not interfere with the cardioprotective benefits of aspirin the way ibuprofen can1
Visit the Resource Library to explore patient and practice support resources.
TYLENOL® is an appropriate analgesic choice to consider for patients on aspirin heart therapy1
Updated NSAID warnings: help your patients understand risks
The U.S. Food and Drug Administration (FDA) required an update to the Drug Facts labeling of all adult and pediatric non-aspirin OTC nonsteroidal anti-inflammatory drugs (NSAIDs), for example Motrin®, Advil®, and Aleve® products. These strengthen and expand existing warnings relating to the risk of heart attack and stroke associated with NSAIDs.6
TYLENOL® does not have a cardiovascular risk warning on its label
Download the NSAID Warning Comparison Guide for more information.
*When symptoms are not controlled by nonpharmacological approaches.
REFERENCES: 1. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817. 2. American Heart Association. Heart disease and stroke statistics 2017 at-a-glance. https://healthmetrics.heart.org/wp-content/uploads/2017/06/Heart-Disease-and-Stroke-Statistics-2017-ucm_491265.pdf. Accessed January 12, 2018. 3. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634-1642. 4. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease. JAMA. 2007;297(18):2018-2024. 5. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation. 2008;118(8):1894-1909. 6. U.S. Food and Drug Administration. FDA strengthens warning of heart attack and stroke risk for non-steroidal anti-inflammatory drugs. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm453610.htm. Accessed January 12, 2018. 7. Rahman MM, Kopec JA, Cibere J, Goldsmith CH, Anis AH. The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study. BMJ Open. 2013;3(5):e002624.